Inoviv Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 21

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 13

Inoviv General Information

Description

Developer of a proteomics platform intended to provide molecular insights into drug response. The company's platform uses an accurate, fully quantitative, and targeted biomarker analysis to accelerate clinical trials in multiple disease areas, enabling pharmaceutical companies to run successful clinical trials and maximize access to marketed therapies.

Contact Information

Website
www.inoviv.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Fox Court 14 Grays Inn Road
  • 136 High Holborn
  • London WC1X 8HN
  • England, United Kingdom
+44 020
Primary Industry
Drug Delivery
Other Industries
Other Healthcare Technology Systems
Vertical(s)
Corporate Office
  • Fox Court 14 Grays Inn Road
  • 136 High Holborn
  • London WC1X 8HN
  • England, United Kingdom
+44 020

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Inoviv Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Secondary Transaction - Private Completed Generating Revenue
6. Later Stage VC 30-Jan-2024 Completed Generating Revenue
5. Later Stage VC 28-Jan-2022 Completed Generating Revenue
4. Grant 01-Aug-2020 Completed Generating Revenue
3. Grant 01-May-2020 Completed Generating Revenue
2. Seed Round 01-Jan-2021 $1.03M $1.04M Completed Generating Revenue
1. Accelerator/Incubator 23-Mar-2018 $13.9K $13.9K Completed Generating Revenue
To view Inoviv’s complete valuation and funding history, request access »

Inoviv Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series Seed -2
Series Seed -2
Ordinary
Series Seed -2
Ordinary
Series Seed
Series Seed
Series Seed 6,173 $0.001271 $54.54 $54.54 1x $54.54 3.82%
Ordinary 8,000 $0.001271 $1.59 $1.59 1x $1.59 4.95%
To view Inoviv’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Inoviv Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a proteomics platform intended to provide molecular insights into drug response. The company's platform use
Drug Delivery
London, United Kingdom
21 As of 2025

Uppsala, Sweden
 

Boulder, CO
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Inoviv Competitors (2)

One of Inoviv’s 2 competitors is Olink Proteomics, a Formerly PE-Backed company based in Uppsala, Sweden.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Olink Proteomics Formerly PE-Backed Uppsala, Sweden
SomaLogic Operating Company Formerly PE-Backed Boulder, CO
You’re viewing 2 of 2 competitors. Get the full list »

Inoviv Patents

Inoviv Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202417740-D0 Muscular dystrophy assay Inactive 03-Dec-2024
GB-202415575-D0 Neurodegenrative disease biomarker assay Inactive 22-Oct-2024
GB-202408899-D0 Method for diagnosing and/or classifying the severity of a neurodegenerative disease Inactive 20-Jun-2024
GB-202318092-D0 Muscular dystrophy assay Inactive 27-Nov-2023
GB-202316201-D0 Method for diagnosing and/or classifying the severity of a neurodegenerative disease Inactive 23-Oct-2023
To view Inoviv’s complete patent history, request access »

Inoviv Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Inoviv Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Foresight Group Asset Manager Minority
Foresight Ventures VCT Venture Capital Minority
Kinled Holding Family Office Minority
Verve Ventures Venture Capital Minority
Beast Ventures Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

Inoviv FAQs

  • When was Inoviv founded?

    Inoviv was founded in 2018.

  • Where is Inoviv headquartered?

    Inoviv is headquartered in London, United Kingdom.

  • What is the size of Inoviv?

    Inoviv has 21 total employees.

  • What industry is Inoviv in?

    Inoviv’s primary industry is Drug Delivery.

  • Is Inoviv a private or public company?

    Inoviv is a Private company.

  • What is Inoviv’s current revenue?

    The current revenue for Inoviv is .

  • How much funding has Inoviv raised over time?

    Inoviv has raised $8.43M.

  • Who are Inoviv’s investors?

    Foresight Group, Foresight Ventures VCT, Kinled Holding, Verve Ventures, and Beast Ventures are 5 of 13 investors who have invested in Inoviv.

  • Who are Inoviv’s competitors?

    Olink Proteomics and SomaLogic Operating Company are competitors of Inoviv.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process